Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine - Luxembourg, Alain; Brown, Darron; Bouchard, Celine; Giuliano, Anna R; Iversen, Ole-Erik; Joura, Elmar A; Penny, Mary E; Restrepo, Jaime A; Romaguera, Josefina; Maansson, Roger; Moeller, Erin; Ritter, Michael; et al. (Human vaccines & immunotherapeutics, 2015)
Keywords: Adolescent; Adult; Antibodies, Viral - blood; Chemistry, Pharmaceutical; CI, confidence interval; cLIA, competitive Luminex Immunoassay; dose selection; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Female; formulation; GMTs, geometric mean titers; HPV; HPV, human papillomavirus vaccine; Humans; immunogenicity; IVRS, Interactive Voice Response System; Papillomavirus Vaccines - administration & dosage; Papillomavirus Vaccines - adverse effects; Papillomavirus Vaccines - immunology; Placebos - administration & dosage; PPI, per-protocol immunogenicity; Research Paper; Treatment Outcome; vaccine; Vaccines, Virus-Like Particle - administration & dosage; Vaccines, Virus-Like Particle - adverse effects; Vaccines, Virus-Like Particle - immunology; VLP, virus-like particle; Young Adult; HPV, human papillomavirus vaccine; CI, confidence interval; vaccine; IVRS, Interactive Voice Response System; PPI, per-protocol immunogenicity; formulation; VLP, virus-like particle; dose selection; GMTs, geometric mean titers; cLIA, competitive Luminex Immunoassay; immunogenicity; HPV